Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| enGene Therapeutics Inc.ENGN · Entity 6638 | Chief Technology Officer | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
enGene Therapeutics Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.53 · Expires 2036-01-30 | Direct | 195,000 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 195,000 · Balance 195,000 F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 16:07 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $9.53 | $0.00 |
DisclosureSEC source: 0000929638-26-000479 · form4.xml · derivative · entry 1 Connolly Joan · CIK 0002041481 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Shares · 195,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. Read SEC document |
| October 21, 2024 Filed Oct 22, 2024 16:07 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0000929638-24-003557 · form4.xml · derivative · entry 1 Connolly Joan · CIK 0002041481 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Shares · 210,000 shares Expires 2034-10-21 F1 · derivative.exercise_date: Non-qualified stock option grant awarded pursuant to the Employment Agreement dated October 21, 2024 between Ms. Connolly and enGene USA, Inc. as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on October 21, 2025, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to Ms. Connolly's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.